J Korean Med Sci.  2020 Jun;35(22):e210. 10.3346/jkms.2020.35.e210.

Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19

• Jeong HG
• Lee Y
• Song KH
• Hwang IC
• Kim ES
• Cho YJ

• KMID: 2502611
• DOI: http://doi.org/10.3346/jkms.2020.35.e210

Abstract

We report a rapidly deteriorating coronavirus disease 2019 (COVID-19) patient, a-58-year-old woman, with severe acute respiratory distress syndrome and shock with hyperpyrexia up to 41.8°C, probably due to the cytokine storm syndrome. Considering extracorporeal membrane oxygenation (ECMO) as the last resort, we applied therapeutic temperature modulation for management of hyperpyrexia. The patient demonstrated rapid improvement in oxygenation and shock after achieving normothermia, and fully recovered from COVID-19 three weeks later. Therapeutic temperature modulation may have successfully offloaded the failing cardiorespiratory system from metabolic cost and hyperinflammation induced by hyperpyrexia. The therapeutic temperature modulation can safely be applied in a specific group of patients with cytokine storm syndrome and hyperpyrexia, which may reduce the number of patients requiring ECMO in the global medical resource shortage.

Keyword

SARS-CoV-2; COVID-19; Fever; Therapeutic Temperature Modulation

Figure

• 

  Fig. 1 Chest radiographs on (A) Day 1, (B) Day 2, (C) Day 3, (D) Day 5, (E) Day 8, and (F) Day 22 of hospitalization.

• 

  Fig. 2 Body temperature, the ratio of partial pressure of arterial oxygen and fraction of inspired oxygen (PaO2/FiO2), and heart rate during hyperpyrexia with subsequent changes indicating the effect of therapeutic temperature modulation.

Reference

1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033–1034. PMID: 32192578.

2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507–513. PMID: 32007143.

3. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39(5):405–407. PMID: 32362390.

4. Cho YJ, Moon JY, Shin ES, Kim JH, Jung H, Park SY, et al. Clinical practice guideline of acute respiratory distress syndrome. Tuberc Respir Dis (Seoul). 2016; 79(4):214–233. PMID: 27790273.

5. Doyle JF, Schortgen F. Should we treat pyrexia? And how do we do it? Crit Care. 2016; 20(1):303. PMID: 27716372.

6. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015; 15(6):335–349. PMID: 25976513.

7. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020; 8(4):e24. PMID: 32178774.